Enrollment under way for study of PET agent in patients with MCI

03/28/2013 | News-Medical.Net

Navidea Biopharmaceuticals said enrollment has started for a Phase IIb trial that will test the safety and efficacy of its PET imaging agent NAV4694. The trial is meant to test whether the agent can detect amyloid plaque in patients with mild cognitive impairment and whether it can help pinpoint the patients likely to progress to Alzheimer's disease. Enrollment will take place at five U.S. locations.

View Full Article in:

News-Medical.Net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ